The following is a summary of “Effect of spesolimab on sustained disease control in patients with generalized pustular ...

The Scottish Medicines Consortium has approved two new drugs for use with patients via the NHS. Two new medicines have been ...

Spesolimab (formerly BI 655130), which is vying to become the first IL-36 inhibitor to reach the market, has now been shown to stop GPP flares in their tracks in some patients, in a phase 2 trial ...

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

the first trial to study subcutaneous Spevigo ® (spesolimab-sbzo) in patients with GPP when not experiencing a flare.

We are encouraged by the improvements observed in patient-reported outcomes with spesolimab. These studies strengthen our commitment to delivering innovative treatments for those living with ...

TWO new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish Medicines ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Boehringer Ingelheim announced new analyses to be presented at the American Academy of Dermatology (AAD) annual meeting in Orlando that explore the effect that SPEVIGO® (spesolimab-sbzo) may have on ...